| Expression pattern: |
UP |
| Associated gene: |
METTL14, MAP3K9, Ago2 |
| Associated microRNA: |
miR-186-3p |
| Biological function: |
Promotes GC cell growth, colony formation, invasion, metastasis, tumorigenesis and cisplatin/DDP resistance; circUGGT2 knockdown suppresses these malignant phenotypes. |
| Molecular mechanism: |
METTL14-dependent m6A modification downregulates circUGGT2; circUGGT2 acts as a miR-186-3p sponge to upregulate MAP3K9, thereby promoting GC progression and DDP resistance. |
| Biological pathway or process: |
m6A modification (other); ceRNA regulation (promotes); proliferation (promotes); invasion (promotes); metastasis (promotes); chemoresistance (promotes) |
| Detected method: |
Q
H
|
| Validation methods: |
RNase R Treatment; RT-qPCR; Microarray; MeRIP / MeRIP-seq; RIP (RNA Immunoprecipitation); FISH / smFISH; Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; Luciferase Reporter Assay; Bioinformatics Analysis; Transfection; MTT; Colony Formation Assay; Transwell Assay; Western Blot; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Survival Analysis |
| Clinical significance: |
Upregulated circUGGT2 is associated with poor overall survival in GC patients and may provide a prognostic and therapeutic target for GC. |
| Description: |
circUGGT2 is an upregulated oncogenic circRNA in gastric cancer and cisplatin-resistant GC cells. METTL14-dependent m6A modification reduces circUGGT2 expression, while circUGGT2 promotes tumor growth, invasion, metastasis and DDP resistance by sponging miR-186-3p and upregulating MAP3K9. High circUGGT2 expression is associated with poor overall survival in GC patients. |
| Confidence score: |
0.8583 |